Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
547 Leser
Artikel bewerten:
(2)

Decision by the Disciplinary Committee regarding Brighter AB

Finanznachrichten News
Stockholm, November 23, 2022- The Disciplinary Committee of Nasdaq Stockholm
has found that Brighter AB (the "Company") has breached the Nasdaq First North
Growth Market Rulebook (the "Rulebook") and therefore ordered the Company to
pay a fine of eight annual fees, corresponding to an amount of approximately
SEK 1,500,000. 

The Disciplinary Committee concludes that the Company on several occasions
between 2020 and 2022 has breached Article 17 of the EU Market Abuse Regulation
("MAR") and the obligation to disclose inside information in a manner that
enables a complete and correct assessment of it, by: 

 -- not, in its disclosures of distribution agreements, having included
   information that the agreements were conditional upon regulatory approvals,
 -- having disclosed incorrect information about the subscription price for a
   warrant that the Company intended to issue,
 -- having disclosed misleading information regarding the terms for employment
   of the Company's CEO.

The Disciplinary Committee concludes that the Company, through these
violations, consequently also breached item 4.1 of the Rulebook. 

The Disciplinary Committee further concludes that the Company did not hold its
annual general meeting 2021 within the deadline set out in the Swedish
Companies Act, and that the Company thereby breached item 1.3 of the Rulebook. 

The Disciplinary Committee takes a serious view of the Company's violations and
orders the Company to pay a fine of eight annual fees. 

The Disciplinary Committee's decision is available at:

https://www.nasdaq.com/solutions/decisions-sanctions-stockholm-2022

About the Disciplinary Committee

The role of Nasdaq Stockholm's Disciplinary Committee is to consider suspicions
regarding whether Exchange Members or listed companies have breached the rules
and regulations applying on the Exchange. If the Exchange suspects that a
member or company has acted in breach of the rules, the matter is referred to
the Disciplinary Committee. Nasdaq Stockholm investigates the suspicions and
pursues the matter and the Disciplinary Committee issues a ruling regarding
possible sanctions. The sanctions possible for listed companies are a warning,
a fine or delisting. The sanctions possible for Exchange Members are a warning,
a fine or debarment. Fines paid are not included in the Exchange's business but
are attributed to a foundation supporting research in the securities market.
The Disciplinary Committee's Chairman and Deputy Chairman must be lawyers with
experience of serving as judges. At least two of the other members of the
Committee must have in-depth insight into the workings of the securities
market. 

Members: Former Supreme Court Justice Marianne Lundius (Chairman), Supreme
Court Justice Petter Asp (Deputy Chairman), Supreme Court Justice Johan
Danelius, Company Director Anders Oscarsson, Company Director Jack Junel,
Company Director Joakim Strid, Lawyer Wilhelm Lüning, Lawyer Patrik Marcelius,
Lawyer Erik Sjöman, MBA Ragnar Boman, MBA Carl Johan Högbom, Authorized Public
Accountant Magnus Svensson Henryson and Former Authorized Public Accountant
Svante Forsberg. 

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital
markets and other industries. Our diverse offering of data, analytics, software
and services enables clients to optimize and execute their business vision with
confidence. To learn more about the company, technology solutions and career
opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. 

Nasdaq Media Contact

Erik Gruvfors
+46 73 449 78 12
erik.gruvfors@nasdaq.com
© 2022 GlobeNewswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.